Healthpeak Properties, Inc. DOC is slated to report its fourth-quarter 2024 results on Feb. 3, after market close. While the quarterly results are expected to reflect year-over-year growth in revenues, funds from operations (FFO) per share might exhibit a decline.
See the Zacks Earnings Calendar to stay ahead of market-making news.
In the last reported quarter, this healthcare real estate investment trust (REIT) posted an FFO as adjusted per share of 45 cents, beating the Zacks Consensus Estimate by a penny. Results reflected better-than-anticipated revenues. Moreover, growth in total merger-combined same-store cash (adjusted) net operating income was witnessed across the portfolio.
In the preceding four quarters, Healthpeak’s FFO, as adjusted per share, surpassed the Zacks Consensus Estimate on all occasions, with the average beat being 2.26%. The graph below depicts this surprise history:
Healthpeak Properties, Inc. price-eps-surprise | Healthpeak Properties, Inc. Quote
The increasing life expectancy of the U.S. population and biopharma drug development growth opportunities have promoted lab real estate market fundamentals. Healthpeak’s focus on the lab segment is a strategic fit and is expected to have been positively impacted by this tailwind, aiding revenue growth in the fourth quarter.
Moreover, the senior citizen population is on the rise, and the healthcare expenditure of this age cohort is usually on the higher end compared with the general population. Healthpeak’s continuing care retirement community portfolio, which refers to its retirement communities that include independent living, assisted living and skilled nursing units, is anticipated to have benefited from this positive expenditure trend, supporting the segment’s quarterly performance.
For the fourth quarter, the Zacks Consensus Estimate for DOC’s rental and related revenues currently stands at $544 million, implying growth of 31.9% from the prior-year period’s reported figure.
The Zacks Consensus Estimate for fourth-quarter total revenues is pegged at $689.2 million, indicating a rise of 24.5% from the year-ago reported number.
However, high interest expenses during the fourth quarter are likely to have been a spoilsport for Healthpeak.
Before the fourth-quarter earnings release, the company’s activities were inadequate to gain analysts’ confidence. The Zacks Consensus Estimate for the quarterly FFO per share has remained unchanged at 45 cents over the past three months. The figure suggests a 2.17% decrease from the year-ago quarter’s tally.
Our proven model does not conclusively predict a surprise in terms of FFO per share for DOC this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an FFO beat, which is not the case here.
Healthpeak currently has an Earnings ESP of -0.74% and carries a Zacks Rank of 3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are two stocks from the broader REIT sector — $Vornado Realty Trust(VNO-N)$ VNO and Ventas VTR — that you may want to consider, as our model shows that these have the right combination of elements to report a surprise this quarter.
Vornado Realty is slated to report quarterly numbers on Feb. 10. VNO has an Earnings ESP of +2.25% and a Zacks Rank of 3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Ventas is slated to report quarterly numbers on Feb. 12. VTR has an Earnings ESP of +0.89% and carries a Zacks Rank of 3 at present.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ventas, Inc. (VTR) : Free Stock Analysis Report
Vornado Realty Trust (VNO) : Free Stock Analysis Report
Healthpeak Properties, Inc. (DOC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.